Stockreport

Enlivex Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating AllocetraTM in up to 46 Patients with Thumb Osteoarthritis

Enlivex Therapeutics Ltd. - Ordinary Shares  (ENLV) 
PDF   First patient dosed with AllocetraTM in thumb osteoarthritis, a degenerative, debilitating and progressive disease that affects millions of peopleThumb osteoarthritis [Read more]